13F holdings · Q2 2026
What is Baker Bros. Advisors buying?
Baker Bros. Advisors's 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026: its largest reported positions and every significant change since Q1 2026.
Reported holdings$19.96B
QuarterQ2 2026
New positions6
Exits and cuts1
Biggest moves in Q2 2026
-
FTH · New position: 1.29M sh (~$32.2M, 0.2% of book)
-
NTLA · New position: 930.2K sh (~$15.7M, 0.1% of book)
-
PBLS · New position: 500.0K sh (~$13.7M, 0.1% of book)
-
AVLN · New position: 350.0K sh (~$11.5M, 0.1% of book)
-
TNGX · New position: 333.3K sh (~$10.4M, 0.1% of book)
-
AVTX · New position: 550.0K sh (~$10.2M, 0.1% of book)
-
IDYA · Added +27% to 5.01M sh (~$186.7M, 0.9% of book)
-
RLAY · Added +144% to 2.83M sh (~$52.9M, 0.3% of book)
-
CLDX · Added +78% to 1.18M sh (~$44.0M, 0.2% of book)
-
RCUS · Added +103% to 844.8K sh (~$26.0M, 0.1% of book)
-
VSTM · Added +327% to 2.50M sh (~$9.5M, 0.0% of book)
-
EWTX · Cut -44% to 3.70M sh
Top holdings
| Holding | Value | % of portfolio | Change in shares |
|---|---|---|---|
| INCYIncyte Corp. | $3.49B | 17.5% | +0% |
| BEIGFBeOne Medicines Ltd. | $2.51B | 12.6% | +0% |
| RVMDRevolution Medicines, Inc. | $2.14B | 10.7% | +20% |
| MDGLMadrigal Pharmaceuticals, Inc. | $1.15B | 5.8% | +0% |
| ACADAcadia Pharmaceuticals Inc. | $1.09B | 5.4% | +0% |
| KYMRKymera Therapeutics, Inc. | $992.7M | 5.0% | +0% |
| INSMINSMED Inc | $937.8M | 4.7% | +19% |
| CELCCelcuity Inc. | $828.2M | 4.2% | +0% |
| KODKodiak Sciences Inc. | $776.1M | 3.9% | +0% |
| RYTMRhythm Pharmaceuticals, Inc. | $622.3M | 3.1% | +0% |
| PRAXPraxis Precision Medicines, Inc. | $587.0M | 2.9% | +0% |
| ALKSAlkermes plc. | $524.6M | 2.6% | +0% |
| SMMTSummit Therapeutics Inc. | $477.7M | 2.4% | -10% |
| GRALGRAIL, Inc. | $275.0M | 1.4% | +0% |
| ABCLAbCellera Biologics Inc. | $259.1M | 1.3% | +9% |
| IMVTImmunovant, Inc. | $209.4M | 1.0% | -0% |
| IDYAIDEAYA Biosciences, Inc. | $186.7M | 0.9% | +27% |
| KNSAKiniksa Pharmaceuticals International, plc | $181.3M | 0.9% | +0% |
| ROIVRoivant Sciences Ltd. | $166.9M | 0.8% | -3% |
| ARWRArrowhead Pharmaceuticals, Inc. | $162.4M | 0.8% | +0% |
From BAKER BROS. ADVISORS LP's Form 13F-HR. 13Fs list long US-listed positions at quarter end and are filed up to 45 days later; they don't show shorts, most hedges or trades made since. View the filing on SEC EDGAR ↗